Woodward Diversified Capital LLC Boosts Stock Holdings in Pfizer Inc. $PFE

Key Points

• Woodward Diversified Capital LLC increased its holdings in Pfizer Inc. by 75.4% in the second quarter, owning 29,055 shares valued at $704,000.
• Pfizer's stock price rose 6.8%, and the company reported earnings of $0.78 per share for the last quarter, exceeding estimates by $0.20.
• As of the latest analysis, Pfizer has a consensus rating of "Hold" with a target price of $28.29 from various investment analysts.

Woodward Diversified Capital LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 75.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,055 shares of the biopharmaceutical company's stock after buying an additional 12,491 shares during the period. Woodward Diversified Capital LLC's holdings in Pfizer were worth $704,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer in the first quarter worth about $27,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer during the 1st quarter worth $28,000. North Capital Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at $28,000. WPG Advisers LLC purchased a new stake in shares of Pfizer in the 1st quarter worth $35,000. Finally, Horizon Financial Services LLC purchased a new stake in shares of Pfizer in the 1st quarter worth $35,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 6.8%

Shares of PFE opened at $27.21 on Thursday. The business's 50 day moving average is $24.59 and its 200 day moving average is $24.14. The company has a market capitalization of $154.68 billion, a PE ratio of 14.47, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Morgan Stanley lifted their target price on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. UBS Group restated a "neutral" rating and set a $28.00 target price on shares of Pfizer in a research note on Wednesday. Finally, Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $28.29.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.